Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.
ncRNA name
hsa-miR-133b
Specific or universal ncRNAs
Universal ncRNAs
Class
MicroRNA
Biomarker
None
Biomarker application
Upstream regulatory factors
Not available
Downstream target
FGFR1
Cancer name
Triple-Negative Breast Cancer
Cancer site
qRT-PCR,Western blot,Dual-luciferase assay
Treatment type
Chemotherapy
Drug
Cisplatin
Impact of wild-type ncRNA on chemotherapy resistance
Impact of knockdown of ncRNA on chemotherapy resistance
Impact of overexpression of ncRNA on chemotherapy resistance
Down
ncRNA differential expression in
cancer
patients vs. healthy people
Down
Number of patients
Not available
Male patients
Not available
Female patients
Not available
Age range and number
Not available
PMID
Description
miR-133b can inhibit the growth and DDP resistance of TNBC cells by targeting FGFR1 and inactivating the Wnt-Ī²-catenin pathway
Tissue resource
breast cancer tissues and adjacent tissues
human normal mammary epithelial cells MCF-10A
triple-negative breast cancer cell lines MDA-MB-468
triple-negative breast cancer cell lines HCC1395
Experiment
None
Institute
Affiliated Hospital of Southwest Medical University
Otwo Biotech Inc
Country
China
China
Continent
Asia
Asia
Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.